Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, and NJCTTQ, a global pharmaceutical company, have announced that they have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in-class T-cell engagers. The collaboration leverages Abpro’s proprietary DiversImmune™ antibody discovery platform.

Under the terms of the agreement, Abpro is eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties. Abpro will retain all commercial rights for any approved molecules in geographies outside of China and Thailand, while NJCTTQ will retain rights in China. Abpro and NJCTTQ will collaborate globally to pursue pre-clinical and clinical development efforts and, ultimately, commercialization.

Abpro develops therapeutic candidates for immuno-oncology using two proprietary platforms -- DiversImmune™ and Multimab™. To date, the DiversImmune™ platform has generated antibodies for pharmaceutical and biotechnology companies against more than 300 unique targets. Abpro’s Multimab™ bispecific platform then enables the assembly of these antibodies into a variety of bi- and multi-specific antibody formats, tailored to each program. Abpro has leveraged the DiversImmune™ and Multimab™ platforms to develop a pipeline of seven novel immuno-oncology therapeutic candidates, including best-in-class T-cell engagers, as well as programs in ophthalmology and autoimmunity.